← ANALYST RATINGS · TIPRANKS
Acumen Pharmaceuticals (ABOS): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $7.00, the highest $8.00, the lowest $5.00. The average is +314.2% from the last price of $1.69.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $5.00 | Buy | +195.9% | Reiterated | 15.10.26on TipRanks 07:55 | −4.6%next day +2.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $2.00−20.0% | Hold | +18.3% | Reiterated | 02.10.26on TipRanks 02:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 | Hold | +47.9% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Hold | +18.3% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | +18.3% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Hold | +18.3% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 → $2.00−20.0% | Hold | +18.3% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | +18.3% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $8.00 | Buy | +373.4% | Reiterated | 17.09.26on TipRanks 04:55 | −2.7%next day +3.0% · 5 days −13.9% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | $8.00 | Buy | +373.4% | Reiterated | 16.09.26on TipRanks Sep 17 05:50 | −9.2%next day −2.7% · 5 days −13.8% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $4.00 → $5.00+25.0% | Buy | +195.9% | Reiterated | 15.09.26on TipRanks 06:20 | +4.0%next day −9.2% · 5 days −10.7% | ↗ |
| Dev Prasad★★★★★★★★★★#663 · hits 80% · avg +91.6% | Lucid Capital | $6.00 | Buy | +255.0% | Initiated | 17.12.25on TipRanks 07:15 | −1.3%next day +2.7% · 5 days +2.2% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $10.00 | Buy | +491.7% | Reiterated | 16.12.25on TipRanks Jan 23 23:13 | +2.2%next day −1.3% · 5 days +1.7% | |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Acumen Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $7.00 at a price of $2.22 (+215.3%); now: $7.00 at $1.69 (+314.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 3 | 4 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.39 (from $-0.49 to $-0.24). Last quarter: $-0.45.
Best top-analyst consensus in the sector · Healthcare
About Acumen Pharmaceuticals
- CEO: Daniel J. O'Connell
- Employees: 61
- 1210-1220 Washington St., Newton, MA, 02465, US
- acumenpharm.com
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Data from the stock’s TipRanks forecast page, read 88 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗